<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:40 -0700</creation_date>
  <update_date>2013-05-27 11:30:14 -0600</update_date>
  <accession>HMDBP00975</accession>
  <secondary_accessions>
    <accession>6263</accession>
    <accession>HMDBP06114</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>COX-2</synonym>
    <synonym>Cyclooxygenase-2</synonym>
    <synonym>PGH synthase 2</synonym>
    <synonym>PGHS-2</synonym>
    <synonym>PHS II</synonym>
    <synonym>Prostaglandin H2 synthase 2</synonym>
    <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
  </synonyms>
  <gene_name>PTGS2</gene_name>
  <general_function>Involved in peroxidase activity</general_function>
  <specific_function>Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.
</specific_function>
  <pathways>
    <pathway>
      <name>prostaglandin biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Arachidonic acid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00590</kegg_map_id>
    </pathway>
    <pathway>
      <name>NF-kappa B signaling pathway</name>
      <smpdb_id/>
      <kegg_map_id>map04064</kegg_map_id>
    </pathway>
    <pathway>
      <name>VEGF signaling pathway</name>
      <smpdb_id/>
      <kegg_map_id>map04370</kegg_map_id>
    </pathway>
    <pathway>
      <name>Retrograde endocannabinoid signaling</name>
      <smpdb_id/>
      <kegg_map_id>map04723</kegg_map_id>
    </pathway>
    <pathway>
      <name>Serotonergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04726</kegg_map_id>
    </pathway>
    <pathway>
      <name>Leishmaniasis</name>
      <smpdb_id/>
      <kegg_map_id>map05140</kegg_map_id>
    </pathway>
    <pathway>
      <name>Chemical carcinogenesis</name>
      <smpdb_id/>
      <kegg_map_id>map05204</kegg_map_id>
    </pathway>
    <pathway>
      <name>Small cell lung cancer</name>
      <smpdb_id/>
      <kegg_map_id>map05222</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB03178</accession>
      <name>Heme</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00692</accession>
      <name>Fe2+</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01335</accession>
      <name>Prostaglandin I2</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01879</accession>
      <name>Aspirin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01923</accession>
      <name>Naproxen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01925</accession>
      <name>Ibuprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05014</accession>
      <name>Celecoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01859</accession>
      <name>Acetaminophen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05033</accession>
      <name>Valdecoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01381</accession>
      <name>Prostaglandin H2</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03235</accession>
      <name>Prostaglandin G2</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14260</accession>
      <name>Desmopressin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01999</accession>
      <name>Eicosapentaenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14378</accession>
      <name>Aminosalicylic Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14389</accession>
      <name>Mesalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13851</accession>
      <name>N-Acetyldapsone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14604</accession>
      <name>Nabumetone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14608</accession>
      <name>Ketorolac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13991</accession>
      <name>5'-Hydroxylornoxicam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14623</accession>
      <name>Lenalidomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13995</accession>
      <name>Hydroxycelecoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14643</accession>
      <name>Tolmetin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14656</accession>
      <name>Cisplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14096</accession>
      <name>5'-Hydroxypiroxicam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14713</accession>
      <name>Fenoprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13974</accession>
      <name>4'-Hydroxydiclofenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14743</accession>
      <name>Sulindac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14850</accession>
      <name>Flurbiprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14858</accession>
      <name>Clodronate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14922</accession>
      <name>Mefenamic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13989</accession>
      <name>O-Desmethylnaproxen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14933</accession>
      <name>Sulfasalazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14950</accession>
      <name>Phenylbutazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14952</accession>
      <name>Meloxicam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14959</accession>
      <name>Carprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14994</accession>
      <name>Chlorphenesin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14999</accession>
      <name>Diflunisal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15008</accession>
      <name>Suprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15022</accession>
      <name>Risedronate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15024</accession>
      <name>Bumetanide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01895</accession>
      <name>Salicylic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15074</accession>
      <name>Meclofenamic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15098</accession>
      <name>Bromfenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15126</accession>
      <name>Oxaprozin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15144</accession>
      <name>Ketoprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15149</accession>
      <name>Balsalazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13870</accession>
      <name>cis,trans-5'-Hydroxythalidomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15403</accession>
      <name>Lumiracoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15408</accession>
      <name>Bismuth Subsalicylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15467</accession>
      <name>Drospirenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15469</accession>
      <name>Magnesium salicylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15470</accession>
      <name>Salicylate-sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15471</accession>
      <name>Salsalate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15473</accession>
      <name>Trisalicylate-choline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15488</accession>
      <name>Antrafenine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13840</accession>
      <name>3-Hydroxymethylantipyrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15538</accession>
      <name>Tiaprofenic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13997</accession>
      <name>6-Hydroxymethyletoricoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15573</accession>
      <name>Niflumic Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01897</accession>
      <name>Substance P</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15666</accession>
      <name>Lornoxicam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15678</accession>
      <name>Nepafenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15680</accession>
      <name>Nonoxynol-9</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>heme binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>antioxidant activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peroxidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>response to stimulus</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>response to stress</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>response to oxidative stress</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>caveola</description>
      <go_id>GO:0005901</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum lumen</description>
      <go_id>GO:0005788</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>neuron projection</description>
      <go_id>GO:0043005</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nucleus</description>
      <go_id>GO:0005634</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>protein complex</description>
      <go_id>GO:0043234</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>heme binding</description>
      <go_id>GO:0020037</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>lipid binding</description>
      <go_id>GO:0008289</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen</description>
      <go_id>GO:0016702</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>peroxidase activity</description>
      <go_id>GO:0004601</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>prostaglandin-endoperoxide synthase activity</description>
      <go_id>GO:0004666</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>anagen</description>
      <go_id>GO:0042640</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bone mineralization</description>
      <go_id>GO:0030282</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>brown fat cell differentiation</description>
      <go_id>GO:0050873</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular component movement</description>
      <go_id>GO:0006928</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to hypoxia</description>
      <go_id>GO:0071456</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cyclooxygenase pathway</description>
      <go_id>GO:0019371</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>decidualization</description>
      <go_id>GO:0046697</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>embryo implantation</description>
      <go_id>GO:0007566</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>inflammatory response</description>
      <go_id>GO:0006954</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>memory</description>
      <go_id>GO:0007613</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of calcium ion transport</description>
      <go_id>GO:0051926</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of cell proliferation</description>
      <go_id>GO:0008285</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of synaptic transmission, dopaminergic</description>
      <go_id>GO:0032227</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>ovulation</description>
      <go_id>GO:0030728</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of apoptotic process</description>
      <go_id>GO:0043065</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of brown fat cell differentiation</description>
      <go_id>GO:0090336</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
      <go_id>GO:0090050</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of fever generation</description>
      <go_id>GO:0031622</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of fibroblast growth factor production</description>
      <go_id>GO:0090271</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of nitric oxide biosynthetic process</description>
      <go_id>GO:0045429</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of platelet-derived growth factor production</description>
      <go_id>GO:0090362</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of prostaglandin biosynthetic process</description>
      <go_id>GO:0031394</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of smooth muscle cell proliferation</description>
      <go_id>GO:0048661</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of smooth muscle contraction</description>
      <go_id>GO:0045987</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of synaptic plasticity</description>
      <go_id>GO:0031915</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of synaptic transmission, glutamatergic</description>
      <go_id>GO:0051968</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of transforming growth factor beta production</description>
      <go_id>GO:0071636</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of vasoconstriction</description>
      <go_id>GO:0045907</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation vascular endothelial growth factor production</description>
      <go_id>GO:0010575</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of blood pressure</description>
      <go_id>GO:0008217</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of cell cycle</description>
      <go_id>GO:0051726</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to cytokine stimulus</description>
      <go_id>GO:0034097</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to estradiol stimulus</description>
      <go_id>GO:0032355</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to fructose stimulus</description>
      <go_id>GO:0009750</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to glucocorticoid stimulus</description>
      <go_id>GO:0051384</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to lipopolysaccharide</description>
      <go_id>GO:0032496</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to manganese ion</description>
      <go_id>GO:0010042</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to organic nitrogen</description>
      <go_id>GO:0010243</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to oxidative stress</description>
      <go_id>GO:0006979</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to vitamin D</description>
      <go_id>GO:0033280</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Microsome membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>1</chromosome_location>
    <locus>1q25.2-q25.3</locus>
    <gene_sequence>&gt;1815 bp
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>604</residue_number>
    <molecular_weight>68995.625</molecular_weight>
    <theoretical_pi>7.383</theoretical_pi>
    <pfams>
      <pfam>
        <name>An_peroxidase</name>
        <pfam_id>PF03098</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Prostaglandin G/H synthase 2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>158257766</genbank_protein_id>
  <uniprot_id>P35354</uniprot_id>
  <uniprot_name>PGH2_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1V0X</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AK292167</genbank_gene_id>
  <genecard_id>PTGS2</genecard_id>
  <geneatlas_id>PTGS2</geneatlas_id>
  <hgnc_id>HGNC:9605</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993 Apr 25;268(12):9049-54.</reference_text>
      <pubmed_id>8473346</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hla T, Neilson K: Human cyclooxygenase-2 cDNA.  Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8.</reference_text>
      <pubmed_id>1380156</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, Tanabe T: Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994 May 1;221(3):889-97.</reference_text>
      <pubmed_id>8181472</pubmed_id>
    </reference>
    <reference>
      <reference_text>Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T: Structure of the human cyclo-oxygenase-2 gene.  Biochem J. 1994 Sep 15;302 ( Pt 3):723-7.</reference_text>
      <pubmed_id>7945196</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1.  Nature. 2006 May 18;441(7091):315-21.</reference_text>
      <pubmed_id>16710414</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J, et al.: Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta. 1994 Nov 16;1209(1):130-9.</reference_text>
      <pubmed_id>7947975</pubmed_id>
    </reference>
    <reference>
      <reference_text>Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004 Dec;25(12):2467-72. Epub 2004 Aug 12.</reference_text>
      <pubmed_id>15308583</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti - inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79.</reference_text>
        <pubmed_id>17033106</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60.</reference_text>
        <pubmed_id>17037745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71.</reference_text>
        <pubmed_id>17181859</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16.</reference_text>
        <pubmed_id>17258197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Hall MN, Campos H, Li H, Sesso HD, Stampfer MJ, Willett WC, Ma J: Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):314-21.</reference_text>
        <pubmed_id>17301265</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desmopressin</name>
        <accession>HMDB14260</accession>
      </metabolite>
      <reference>
        <reference_text>Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11.</reference_text>
        <pubmed_id>15644490</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1.</reference_text>
        <pubmed_id>12562875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Ait-Said F, Elalamy I, Werts C, Gomard MT, Jacquemin C, Couetil JP, Hatmi M: Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta. 2003 Feb 20;1631(1):77-84.</reference_text>
        <pubmed_id>12573452</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M: Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci. 2005 Sep;99(1):113-6. Epub 2005 Sep 1.</reference_text>
        <pubmed_id>16141635</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Das UN: Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids? J Assoc Physicians India. 2005 Jul;53:623-7.</reference_text>
        <pubmed_id>16190133</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Chene G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M, Pipy B: n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta. 2007 May;1771(5):576-89. Epub 2007 Mar 16.</reference_text>
        <pubmed_id>17459764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eicosapentaenoic acid</name>
        <accession>HMDB01999</accession>
      </metabolite>
      <reference>
        <reference_text>Vecchio AJ, Simmons DM, Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2.  J Biol Chem. 2010 Jul 16;285(29):22152-63. Epub 2010 May 12.</reference_text>
        <pubmed_id>20463020</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.</reference_text>
        <pubmed_id>14742690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease.  Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.</reference_text>
        <pubmed_id>12463455</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.</reference_text>
        <pubmed_id>16855178</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.</reference_text>
        <pubmed_id>12208114</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminosalicylic Acid</name>
        <accession>HMDB14378</accession>
      </metabolite>
      <reference>
        <reference_text>Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.</reference_text>
        <pubmed_id>9256165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.</reference_text>
        <pubmed_id>14742690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease.  Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.</reference_text>
        <pubmed_id>12463455</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.</reference_text>
        <pubmed_id>16855178</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.</reference_text>
        <pubmed_id>12208114</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mesalazine</name>
        <accession>HMDB14389</accession>
      </metabolite>
      <reference>
        <reference_text>Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.</reference_text>
        <pubmed_id>9256165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Acetyldapsone</name>
        <accession>HMDB13851</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nabumetone</name>
        <accession>HMDB14604</accession>
      </metabolite>
      <reference>
        <reference_text>Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22.</reference_text>
        <pubmed_id>11153163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nabumetone</name>
        <accession>HMDB14604</accession>
      </metabolite>
      <reference>
        <reference_text>Roy HK, Karolski WJ, Ratashak A: Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer. 2001 May 15;92(4):609-15.</reference_text>
        <pubmed_id>11304699</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nabumetone</name>
        <accession>HMDB14604</accession>
      </metabolite>
      <reference>
        <reference_text>van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ: A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol. 2002 Jun;53(6):644-7.</reference_text>
        <pubmed_id>12047490</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nabumetone</name>
        <accession>HMDB14604</accession>
      </metabolite>
      <reference>
        <reference_text>Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, Ekbom A: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64(20):2315-43; discussion 2344-5.</reference_text>
        <pubmed_id>15456329</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nabumetone</name>
        <accession>HMDB14604</accession>
      </metabolite>
      <reference>
        <reference_text>Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995 Aug;109(2):524-30.</reference_text>
        <pubmed_id>7615202</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nabumetone</name>
        <accession>HMDB14604</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketorolac</name>
        <accession>HMDB14608</accession>
      </metabolite>
      <reference>
        <reference_text>Hocherl K, Kammerl MC, Schumacher K, Endemann D, Grobecker HF, Kurtz A: Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake. Am J Physiol Renal Physiol. 2002 Aug;283(2):F294-301.</reference_text>
        <pubmed_id>12110513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketorolac</name>
        <accession>HMDB14608</accession>
      </metabolite>
      <reference>
        <reference_text>Blais V, Zhang J, Rivest S: In altering the release of glucocorticoids, ketorolac exacerbates the effects of systemic immune stimuli on expression of proinflammatory genes in the brain. Endocrinology. 2002 Dec;143(12):4820-7.</reference_text>
        <pubmed_id>12446609</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketorolac</name>
        <accession>HMDB14608</accession>
      </metabolite>
      <reference>
        <reference_text>Ma W, Eisenach JC: Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and dynorphin in the dorsal horn of rats with nerve injury or inflammation. Neuroscience. 2003;121(3):681-90.</reference_text>
        <pubmed_id>14568028</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketorolac</name>
        <accession>HMDB14608</accession>
      </metabolite>
      <reference>
        <reference_text>Ma W, Eisenach JC: Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience. 2003;121(3):691-704.</reference_text>
        <pubmed_id>14568029</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketorolac</name>
        <accession>HMDB14608</accession>
      </metabolite>
      <reference>
        <reference_text>Padi SS, Jain NK, Singh S, Kulkarni SK: Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol. 2004 Apr 26;491(1):69-76.</reference_text>
        <pubmed_id>15102535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxylornoxicam</name>
        <accession>HMDB13991</accession>
      </metabolite>
      <reference>
        <reference_text>Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63.</reference_text>
        <pubmed_id>11563332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxylornoxicam</name>
        <accession>HMDB13991</accession>
      </metabolite>
      <reference>
        <reference_text>Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12.</reference_text>
        <pubmed_id>9152412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxylornoxicam</name>
        <accession>HMDB13991</accession>
      </metabolite>
      <reference>
        <reference_text>Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43.</reference_text>
        <pubmed_id>15943176</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxylornoxicam</name>
        <accession>HMDB13991</accession>
      </metabolite>
      <reference>
        <reference_text>Yilmaz H, Gurel S, Ozdemir O: The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42.</reference_text>
        <pubmed_id>16245223</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxylornoxicam</name>
        <accession>HMDB13991</accession>
      </metabolite>
      <reference>
        <reference_text>Galvao RI, Diogenes JP, Maia GC, Filho EA, Vasconcelos SM, de Menezes DB, Cunha GM, Viana GS: Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats.  Neurochem Res. 2005 Jan;30(1):39-46.</reference_text>
        <pubmed_id>15756931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxylornoxicam</name>
        <accession>HMDB13991</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lenalidomide</name>
        <accession>HMDB14623</accession>
      </metabolite>
      <reference>
        <reference_text>Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8.</reference_text>
        <pubmed_id>15598423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lenalidomide</name>
        <accession>HMDB14623</accession>
      </metabolite>
      <reference>
        <reference_text>Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia.  Semin Oncol. 2003 Apr;30(2):275-81.</reference_text>
        <pubmed_id>12720152</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002 Jun;122(7):1913-23.</reference_text>
        <pubmed_id>12055598</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.  Cleve Clin J Med. 2002;69 Suppl 1:SI40-6.</reference_text>
        <pubmed_id>12086292</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Reddy BS, Rao CV: Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.  J Environ Pathol Toxicol Oncol. 2002;21(2):155-64.</reference_text>
        <pubmed_id>12086402</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib.  Drug Saf. 2002;25(7):537-44.</reference_text>
        <pubmed_id>12093311</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 2002 Oct 8;184(1):7-12.</reference_text>
        <pubmed_id>12104042</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolmetin</name>
        <accession>HMDB14643</accession>
      </metabolite>
      <reference>
        <reference_text>Burdan F, Szumilo J, Klepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L: Gastrointestinal and hepatic toxicity of selective and non-selective cyclooxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacol Res. 2004 Nov;50(5):533-43.</reference_text>
        <pubmed_id>15458776</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolmetin</name>
        <accession>HMDB14643</accession>
      </metabolite>
      <reference>
        <reference_text>Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204.</reference_text>
        <pubmed_id>9253954</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolmetin</name>
        <accession>HMDB14643</accession>
      </metabolite>
      <reference>
        <reference_text>Kirkova M, Alexandova A, Kesiova M, Todorov S: In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs. Auton Autacoid Pharmacol. 2007 Apr;27(2):99-104.</reference_text>
        <pubmed_id>17391279</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolmetin</name>
        <accession>HMDB14643</accession>
      </metabolite>
      <reference>
        <reference_text>Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74.</reference_text>
        <pubmed_id>14613550</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolmetin</name>
        <accession>HMDB14643</accession>
      </metabolite>
      <reference>
        <reference_text>Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7.</reference_text>
        <pubmed_id>10465690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolmetin</name>
        <accession>HMDB14643</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Tusgaard B, Norregaard R, Jensen AM, Wang G, Topcu SO, Wang Y, Nielsen S, Frokiaer J: Cisplatin decreases renal cyclooxygenase-2 expression and activity in rats.  Acta Physiol (Oxf). 2011 May;202(1):79-90. doi: 10.1111/j.1748-1716.2011.02257.x.       Epub 2011 Mar 22.</reference_text>
        <pubmed_id>21272267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxypiroxicam</name>
        <accession>HMDB14096</accession>
      </metabolite>
      <reference>
        <reference_text>Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73.</reference_text>
        <pubmed_id>10381057</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxypiroxicam</name>
        <accession>HMDB14096</accession>
      </metabolite>
      <reference>
        <reference_text>Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809.</reference_text>
        <pubmed_id>11785774</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxypiroxicam</name>
        <accession>HMDB14096</accession>
      </metabolite>
      <reference>
        <reference_text>Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22.</reference_text>
        <pubmed_id>11153163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxypiroxicam</name>
        <accession>HMDB14096</accession>
      </metabolite>
      <reference>
        <reference_text>Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46.</reference_text>
        <pubmed_id>11952155</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxypiroxicam</name>
        <accession>HMDB14096</accession>
      </metabolite>
      <reference>
        <reference_text>Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats.  Life Sci. 2004 Oct 22;75(23):2807-17.</reference_text>
        <pubmed_id>15464832</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5'-Hydroxypiroxicam</name>
        <accession>HMDB14096</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenoprofen</name>
        <accession>HMDB14713</accession>
      </metabolite>
      <reference>
        <reference_text>Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36.</reference_text>
        <pubmed_id>17050798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 2003 Jan;55(1):51-61.</reference_text>
        <pubmed_id>12534640</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Blomme EA, Chinn KS, Hardy MM, Casler JJ, Kim SH, Opsahl AC, Hall WA, Trajkovic D, Khan KN, Tripp CS: Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br J Dermatol. 2003 Feb;148(2):211-23.</reference_text>
        <pubmed_id>12588370</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Beubler E: [Pharmacology of cyclooxygenase 2 inhibition].  Wien Med Wochenschr. 2003;153(5-6):95-9.</reference_text>
        <pubmed_id>12705061</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Chavez ML, DeKorte CJ: Valdecoxib: a review.  Clin Ther. 2003 Mar;25(3):817-51.</reference_text>
        <pubmed_id>12852704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, Stallings WC, Kurumbail RG, Marnett LJ: A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem. 2003 Nov 14;278(46):45763-9. Epub 2003 Aug 18.</reference_text>
        <pubmed_id>12925531</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulindac</name>
        <accession>HMDB14743</accession>
      </metabolite>
      <reference>
        <reference_text>Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30.</reference_text>
        <pubmed_id>10372826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulindac</name>
        <accession>HMDB14743</accession>
      </metabolite>
      <reference>
        <reference_text>Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 Sep 1;59(17):4356-62.</reference_text>
        <pubmed_id>10485483</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulindac</name>
        <accession>HMDB14743</accession>
      </metabolite>
      <reference>
        <reference_text>Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.  Carcinogenesis. 2000 Feb;21(2):139-46.</reference_text>
        <pubmed_id>10657949</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulindac</name>
        <accession>HMDB14743</accession>
      </metabolite>
      <reference>
        <reference_text>Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000 Oct;37(5):431-502.</reference_text>
        <pubmed_id>11078056</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulindac</name>
        <accession>HMDB14743</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, Gerner EW: Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000 Dec 1;60(23):6607-10.</reference_text>
        <pubmed_id>11118042</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Bayly CI, Black WC, Leger S, Ouimet N, Ouellet M, Percival MD: Structure-based design of COX-2 selectivity into flurbiprofen.  Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12.</reference_text>
        <pubmed_id>10091674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>van Haeringen NJ, van Sorge AA, Carballosa Core-Bodelier VM: Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J Ocul Pharmacol Ther. 2000 Aug;16(4):353-61.</reference_text>
        <pubmed_id>10977131</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Smith T, McCracken J, Shin YK, DeWitt D: Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2). J Biol Chem. 2000 Dec 22;275(51):40407-15.</reference_text>
        <pubmed_id>11006278</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Hinz B, Brune K, Rau T, Pahl A: Flurbiprofen enantiomers inhibit inducible nitric oxide synthase expression in RAW 264.7 macrophages. Pharm Res. 2001 Feb;18(2):151-6.</reference_text>
        <pubmed_id>11405284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25.</reference_text>
        <pubmed_id>10773011</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12.</reference_text>
        <pubmed_id>17562170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management.  Pharmacol Rep. 2008 Sep-Oct;60(5):692-8.</reference_text>
        <pubmed_id>19066416</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clodronate</name>
        <accession>HMDB14858</accession>
      </metabolite>
      <reference>
        <reference_text>Liu L, Igarashi K, Kanzaki H, Chiba M, Shinoda H, Mitani H: Clodronate inhibits PGE(2) production in compressed periodontal ligament cells.  J Dent Res. 2006 Aug;85(8):757-60.</reference_text>
        <pubmed_id>16861295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefenamic acid</name>
        <accession>HMDB14922</accession>
      </metabolite>
      <reference>
        <reference_text>Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84.</reference_text>
        <pubmed_id>7832763</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefenamic acid</name>
        <accession>HMDB14922</accession>
      </metabolite>
      <reference>
        <reference_text>Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study. Eur J Pharmacol. 2007 Feb 5;556(1-3):190-9. Epub 2006 Oct 27.</reference_text>
        <pubmed_id>17150210</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefenamic acid</name>
        <accession>HMDB14922</accession>
      </metabolite>
      <reference>
        <reference_text>Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. Eur J Pharmacol. 2005 Mar 28;511(2-3):137-42.</reference_text>
        <pubmed_id>15792781</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefenamic acid</name>
        <accession>HMDB14922</accession>
      </metabolite>
      <reference>
        <reference_text>Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21.</reference_text>
        <pubmed_id>9626023</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefenamic acid</name>
        <accession>HMDB14922</accession>
      </metabolite>
      <reference>
        <reference_text>Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW, Powell JT: Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999 Jul 6;100(1):48-54.</reference_text>
        <pubmed_id>10393680</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefenamic acid</name>
        <accession>HMDB14922</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylnaproxen</name>
        <accession>HMDB13989</accession>
      </metabolite>
      <reference>
        <reference_text>Albertini R, Aimbire F, Villaverde AB, Silva JA Jr, Costa MS: COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res. 2007 Jun;56(6):228-9.</reference_text>
        <pubmed_id>17607546</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylnaproxen</name>
        <accession>HMDB13989</accession>
      </metabolite>
      <reference>
        <reference_text>Dhir A, Naidu PS, Kulkarni SK: Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Dec;16(8):691-7. Epub 2007 Jul 2.</reference_text>
        <pubmed_id>17604186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylnaproxen</name>
        <accession>HMDB13989</accession>
      </metabolite>
      <reference>
        <reference_text>Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007 Jun;21(3):297-306.</reference_text>
        <pubmed_id>17521299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylnaproxen</name>
        <accession>HMDB13989</accession>
      </metabolite>
      <reference>
        <reference_text>White WB: Cardiovascular effects of the selective cyclooxygenase-2 inhibitors.  Subcell Biochem. 2007;42:145-58.</reference_text>
        <pubmed_id>17612049</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylnaproxen</name>
        <accession>HMDB13989</accession>
      </metabolite>
      <reference>
        <reference_text>Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Langstrom G, Andersson T: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clin Drug Investig. 2005;25(11):731-40.</reference_text>
        <pubmed_id>17532719</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylnaproxen</name>
        <accession>HMDB13989</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.</reference_text>
        <pubmed_id>14742690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease.  Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.</reference_text>
        <pubmed_id>12463455</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.</reference_text>
        <pubmed_id>16855178</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.</reference_text>
        <pubmed_id>12208114</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfasalazine</name>
        <accession>HMDB14933</accession>
      </metabolite>
      <reference>
        <reference_text>Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.</reference_text>
        <pubmed_id>9256165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenylbutazone</name>
        <accession>HMDB14950</accession>
      </metabolite>
      <reference>
        <reference_text>Arifah AK, Lees P: Pharmacodynamics and pharmacokinetics of phenylbutazone in calves.  J Vet Pharmacol Ther. 2002 Aug;25(4):299-309.</reference_text>
        <pubmed_id>12213119</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenylbutazone</name>
        <accession>HMDB14950</accession>
      </metabolite>
      <reference>
        <reference_text>Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004 Dec 9;23(57):9247-58.</reference_text>
        <pubmed_id>15489888</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenylbutazone</name>
        <accession>HMDB14950</accession>
      </metabolite>
      <reference>
        <reference_text>Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.</reference_text>
        <pubmed_id>15939622</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenylbutazone</name>
        <accession>HMDB14950</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Poulsen Nautrup B, Horstermann D: [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100.</reference_text>
        <pubmed_id>10220944</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999 May;65(5):533-44.</reference_text>
        <pubmed_id>10340919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73.</reference_text>
        <pubmed_id>10381057</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80.</reference_text>
        <pubmed_id>10381787</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors.  Hypertension. 1999 Nov;34(5):1163-7.</reference_text>
        <pubmed_id>10567199</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carprofen</name>
        <accession>HMDB14959</accession>
      </metabolite>
      <reference>
        <reference_text>Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10.</reference_text>
        <pubmed_id>10895904</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carprofen</name>
        <accession>HMDB14959</accession>
      </metabolite>
      <reference>
        <reference_text>Brideau C, Van Staden C, Chan CC: In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res. 2001 Nov;62(11):1755-60.</reference_text>
        <pubmed_id>11703020</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carprofen</name>
        <accession>HMDB14959</accession>
      </metabolite>
      <reference>
        <reference_text>Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8.</reference_text>
        <pubmed_id>15198222</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carprofen</name>
        <accession>HMDB14959</accession>
      </metabolite>
      <reference>
        <reference_text>Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.</reference_text>
        <pubmed_id>15939622</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carprofen</name>
        <accession>HMDB14959</accession>
      </metabolite>
      <reference>
        <reference_text>Narlawar R, Perez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K: Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91.</reference_text>
        <pubmed_id>17181139</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carprofen</name>
        <accession>HMDB14959</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Fernandez P, Guillen MI, Gomar F, Aller E, Molina P, Alcaraz MJ: A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis. Biochem Pharmacol. 2004 Aug 1;68(3):417-21.</reference_text>
        <pubmed_id>15242808</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diflunisal</name>
        <accession>HMDB14999</accession>
      </metabolite>
      <reference>
        <reference_text>Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56.</reference_text>
        <pubmed_id>12852483</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diflunisal</name>
        <accession>HMDB14999</accession>
      </metabolite>
      <reference>
        <reference_text>Jeske AH: COX-2 inhibitors and dental pain control.  J Gt Houst Dent Soc. 1999 Nov;71(4):39-40.</reference_text>
        <pubmed_id>10825891</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diflunisal</name>
        <accession>HMDB14999</accession>
      </metabolite>
      <reference>
        <reference_text>Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35.</reference_text>
        <pubmed_id>11673972</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diflunisal</name>
        <accession>HMDB14999</accession>
      </metabolite>
      <reference>
        <reference_text>Moore PA, Hersh EV: Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.  J Am Dent Assoc. 2001 Apr;132(4):451-6.</reference_text>
        <pubmed_id>11315375</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diflunisal</name>
        <accession>HMDB14999</accession>
      </metabolite>
      <reference>
        <reference_text>Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53.</reference_text>
        <pubmed_id>8737748</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diflunisal</name>
        <accession>HMDB14999</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Suprofen</name>
        <accession>HMDB15008</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Suprofen</name>
        <accession>HMDB15008</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Suprofen</name>
        <accession>HMDB15008</accession>
      </metabolite>
      <reference>
        <reference_text>Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors.  J Mol Graph Model. 2002 Mar;20(5):359-71.</reference_text>
        <pubmed_id>11885959</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V, Dalle Carbonare L: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163. Epub 2010 Aug 25.</reference_text>
        <pubmed_id>20738860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bumetanide</name>
        <accession>HMDB15024</accession>
      </metabolite>
      <reference>
        <reference_text>Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000 Sep;106(5):681-8.</reference_text>
        <pubmed_id>10974021</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics.  Inflammopharmacology. 2003;11(4):401-13.</reference_text>
        <pubmed_id>15035793</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8.</reference_text>
        <pubmed_id>15070163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91.</reference_text>
        <pubmed_id>15106733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.  Semin Vasc Med. 2003 May;3(2):107-12.</reference_text>
        <pubmed_id>15199473</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42.</reference_text>
        <pubmed_id>15348270</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.</reference_text>
        <pubmed_id>5284360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30.</reference_text>
        <pubmed_id>10639181</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45.</reference_text>
        <pubmed_id>12409963</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8.</reference_text>
        <pubmed_id>15198222</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors.  Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14.</reference_text>
        <pubmed_id>16290292</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclofenamic acid</name>
        <accession>HMDB15074</accession>
      </metabolite>
      <reference>
        <reference_text>Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs.  Ann N Y Acad Sci. 1994 Nov 15;744:50-7.</reference_text>
        <pubmed_id>7825862</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromfenac</name>
        <accession>HMDB15098</accession>
      </metabolite>
      <reference>
        <reference_text>Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.</reference_text>
        <pubmed_id>16846546</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromfenac</name>
        <accession>HMDB15098</accession>
      </metabolite>
      <reference>
        <reference_text>Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S: Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32.</reference_text>
        <pubmed_id>16982289</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromfenac</name>
        <accession>HMDB15098</accession>
      </metabolite>
      <reference>
        <reference_text>Chitturi S, George J: Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22(2):169-83.</reference_text>
        <pubmed_id>12016548</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromfenac</name>
        <accession>HMDB15098</accession>
      </metabolite>
      <reference>
        <reference_text>Cho H, Wolf KJ, Wolf EJ: Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009;3:199-210. Epub 2009 Jun 2.</reference_text>
        <pubmed_id>19668566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaprozin</name>
        <accession>HMDB15126</accession>
      </metabolite>
      <reference>
        <reference_text>Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60.</reference_text>
        <pubmed_id>17024689</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaprozin</name>
        <accession>HMDB15126</accession>
      </metabolite>
      <reference>
        <reference_text>Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94.</reference_text>
        <pubmed_id>9650852</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaprozin</name>
        <accession>HMDB15126</accession>
      </metabolite>
      <reference>
        <reference_text>Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6.</reference_text>
        <pubmed_id>9831331</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaprozin</name>
        <accession>HMDB15126</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25.</reference_text>
        <pubmed_id>12065695</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaprozin</name>
        <accession>HMDB15126</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90.</reference_text>
        <pubmed_id>19952416</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaprozin</name>
        <accession>HMDB15126</accession>
      </metabolite>
      <reference>
        <reference_text>Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. Epub 2009 Mar 26.</reference_text>
        <pubmed_id>19338579</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen</name>
        <accession>HMDB15144</accession>
      </metabolite>
      <reference>
        <reference_text>Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10.</reference_text>
        <pubmed_id>10895904</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen</name>
        <accession>HMDB15144</accession>
      </metabolite>
      <reference>
        <reference_text>Sommerauer M, Ates M, Guhring H, Brune K, Amann R, Peskar BA: Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9.</reference_text>
        <pubmed_id>11729362</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen</name>
        <accession>HMDB15144</accession>
      </metabolite>
      <reference>
        <reference_text>Levoin N, Chretien F, Lapicque F, Chapleur Y: Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7.</reference_text>
        <pubmed_id>11814865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen</name>
        <accession>HMDB15144</accession>
      </metabolite>
      <reference>
        <reference_text>Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40.</reference_text>
        <pubmed_id>14513718</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen</name>
        <accession>HMDB15144</accession>
      </metabolite>
      <reference>
        <reference_text>Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8.</reference_text>
        <pubmed_id>15198222</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen</name>
        <accession>HMDB15144</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84.</reference_text>
        <pubmed_id>19743890</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008 Feb 1;75(3):668-76. Epub 2007 Sep 29.</reference_text>
        <pubmed_id>17981262</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Balsalazide</name>
        <accession>HMDB15149</accession>
      </metabolite>
      <reference>
        <reference_text>Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.</reference_text>
        <pubmed_id>12950415</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Horrobin DF: A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels. Med Hypotheses. 2003 May;60(5):615-23.</reference_text>
        <pubmed_id>12710892</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Hada M, Mizutari K: [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. Gan To Kagaku Ryoho. 2004 Sep;31(9):1407-10.</reference_text>
        <pubmed_id>15446566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8.</reference_text>
        <pubmed_id>15598423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer.  Curr Cancer Drug Targets. 2005 May;5(3):171-93.</reference_text>
        <pubmed_id>15892618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Du GJ, Lin HH, Xu QT, Wang MW: Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005 Aug;43(2):112-9.</reference_text>
        <pubmed_id>15982930</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Capone ML, Tacconelli S, Sciulli MG, Patrignani P: Clinical pharmacology of selective COX-2 inhibitors.  Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58.</reference_text>
        <pubmed_id>14552704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Tacconelli S, Capone ML, Patrignani P: Clinical pharmacology of novel selective COX-2 inhibitors.  Curr Pharm Des. 2004;10(6):589-601.</reference_text>
        <pubmed_id>14965322</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ: Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatol. 2004 Feb;2(2):113-20.</reference_text>
        <pubmed_id>15017615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Kalbag J, Yeh CM, Milosavljev S, Lasseter K, Oberstein S, Rordorf C: No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacol Res. 2004 Aug;50(2):181-6.</reference_text>
        <pubmed_id>15177307</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ: Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50.</reference_text>
        <pubmed_id>15655513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics.  Inflammopharmacology. 2003;11(4):401-13.</reference_text>
        <pubmed_id>15035793</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8.</reference_text>
        <pubmed_id>15070163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91.</reference_text>
        <pubmed_id>15106733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.  Semin Vasc Med. 2003 May;3(2):107-12.</reference_text>
        <pubmed_id>15199473</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42.</reference_text>
        <pubmed_id>15348270</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.</reference_text>
        <pubmed_id>5284360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drospirenone</name>
        <accession>HMDB15467</accession>
      </metabolite>
      <reference>
        <reference_text>Maia H Jr, Casoy J, Athayde C, Valente Filho J, Coutinho EM: The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium. Eur J Contracept Reprod Health Care. 2010 Feb;15(1):35-40.</reference_text>
        <pubmed_id>20063991</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Magnesium salicylate</name>
        <accession>HMDB15469</accession>
      </metabolite>
      <reference>
        <reference_text>Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics.  Inflammopharmacology. 2003;11(4):401-13.</reference_text>
        <pubmed_id>15035793</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Magnesium salicylate</name>
        <accession>HMDB15469</accession>
      </metabolite>
      <reference>
        <reference_text>Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8.</reference_text>
        <pubmed_id>15070163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Magnesium salicylate</name>
        <accession>HMDB15469</accession>
      </metabolite>
      <reference>
        <reference_text>Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91.</reference_text>
        <pubmed_id>15106733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Magnesium salicylate</name>
        <accession>HMDB15469</accession>
      </metabolite>
      <reference>
        <reference_text>Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.  Semin Vasc Med. 2003 May;3(2):107-12.</reference_text>
        <pubmed_id>15199473</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Magnesium salicylate</name>
        <accession>HMDB15469</accession>
      </metabolite>
      <reference>
        <reference_text>Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42.</reference_text>
        <pubmed_id>15348270</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylate-sodium</name>
        <accession>HMDB15470</accession>
      </metabolite>
      <reference>
        <reference_text>Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.  Semin Vasc Med. 2003 May;3(2):107-12.</reference_text>
        <pubmed_id>15199473</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylate-sodium</name>
        <accession>HMDB15470</accession>
      </metabolite>
      <reference>
        <reference_text>Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007 Feb;56(2):337-45.</reference_text>
        <pubmed_id>17259377</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylate-sodium</name>
        <accession>HMDB15470</accession>
      </metabolite>
      <reference>
        <reference_text>Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics.  Inflammopharmacology. 2003;11(4):401-13.</reference_text>
        <pubmed_id>15035793</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylate-sodium</name>
        <accession>HMDB15470</accession>
      </metabolite>
      <reference>
        <reference_text>Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8.</reference_text>
        <pubmed_id>15070163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylate-sodium</name>
        <accession>HMDB15470</accession>
      </metabolite>
      <reference>
        <reference_text>Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91.</reference_text>
        <pubmed_id>15106733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salsalate</name>
        <accession>HMDB15471</accession>
      </metabolite>
      <reference>
        <reference_text>Stichtenoth DO, Zeidler H, Frolich JC: [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase]. Med Klin (Munich). 1998 Jul 15;93(7):407-15.</reference_text>
        <pubmed_id>9711054</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salsalate</name>
        <accession>HMDB15471</accession>
      </metabolite>
      <reference>
        <reference_text>Schaefer MG, Plowman BK, Morreale AP, Egan M: Interaction of rofecoxib and celecoxib with warfarin.  Am J Health Syst Pharm. 2003 Jul 1;60(13):1319-23.</reference_text>
        <pubmed_id>12901032</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salsalate</name>
        <accession>HMDB15471</accession>
      </metabolite>
      <reference>
        <reference_text>Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621-32.</reference_text>
        <pubmed_id>16808554</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salsalate</name>
        <accession>HMDB15471</accession>
      </metabolite>
      <reference>
        <reference_text>Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility.  J Surg Res. 1999 Sep;86(1):50-4.</reference_text>
        <pubmed_id>10452868</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trisalicylate-choline</name>
        <accession>HMDB15473</accession>
      </metabolite>
      <reference>
        <reference_text>Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24.</reference_text>
        <pubmed_id>14680616</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trisalicylate-choline</name>
        <accession>HMDB15473</accession>
      </metabolite>
      <reference>
        <reference_text>Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti - inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79.</reference_text>
        <pubmed_id>17033106</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trisalicylate-choline</name>
        <accession>HMDB15473</accession>
      </metabolite>
      <reference>
        <reference_text>Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60.</reference_text>
        <pubmed_id>17037745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trisalicylate-choline</name>
        <accession>HMDB15473</accession>
      </metabolite>
      <reference>
        <reference_text>Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71.</reference_text>
        <pubmed_id>17181859</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trisalicylate-choline</name>
        <accession>HMDB15473</accession>
      </metabolite>
      <reference>
        <reference_text>Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16.</reference_text>
        <pubmed_id>17258197</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antrafenine</name>
        <accession>HMDB15488</accession>
      </metabolite>
      <reference>
        <reference_text>Albertini R, Aimbire F, Villaverde AB, Silva JA Jr, Costa MS: COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res. 2007 Jun;56(6):228-9.</reference_text>
        <pubmed_id>17607546</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antrafenine</name>
        <accession>HMDB15488</accession>
      </metabolite>
      <reference>
        <reference_text>Dhir A, Naidu PS, Kulkarni SK: Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Dec;16(8):691-7. Epub 2007 Jul 2.</reference_text>
        <pubmed_id>17604186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antrafenine</name>
        <accession>HMDB15488</accession>
      </metabolite>
      <reference>
        <reference_text>Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007 Jun;21(3):297-306.</reference_text>
        <pubmed_id>17521299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antrafenine</name>
        <accession>HMDB15488</accession>
      </metabolite>
      <reference>
        <reference_text>White WB: Cardiovascular effects of the selective cyclooxygenase-2 inhibitors.  Subcell Biochem. 2007;42:145-58.</reference_text>
        <pubmed_id>17612049</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antrafenine</name>
        <accession>HMDB15488</accession>
      </metabolite>
      <reference>
        <reference_text>Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Langstrom G, Andersson T: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clin Drug Investig. 2005;25(11):731-40.</reference_text>
        <pubmed_id>17532719</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antrafenine</name>
        <accession>HMDB15488</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7.</reference_text>
        <pubmed_id>11695253</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Lee YS, Kim H, Brahim JS, Rowan J, Lee G, Dionne RA: Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007 Jun;129(3):279-86. Epub 2006 Dec 18.</reference_text>
        <pubmed_id>17175104</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man.  FASEB J. 2008 Feb;22(2):383-90. Epub 2007 Sep 20.</reference_text>
        <pubmed_id>17884974</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Weinheimer EM, Jemiolo B, Carroll CC, Harber MP, Haus JM, Burd NA, LeMoine JK, Trappe SW, Trappe TA: Resistance exercise and cyclooxygenase (COX) expression in human skeletal muscle: implications for COX-inhibiting drugs and protein synthesis. Am J Physiol Regul Integr Comp Physiol. 2007 Jun;292(6):R2241-8. Epub 2007 Feb       22.</reference_text>
        <pubmed_id>17322116</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiaprofenic acid</name>
        <accession>HMDB15538</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiaprofenic acid</name>
        <accession>HMDB15538</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiaprofenic acid</name>
        <accession>HMDB15538</accession>
      </metabolite>
      <reference>
        <reference_text>Brandt KD, Albrecht ME, Kalasinski LA: Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14.</reference_text>
        <pubmed_id>2277128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiaprofenic acid</name>
        <accession>HMDB15538</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P: Pharmacodynamic of cyclooxygenase inhibitors in humans.  Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94. Epub 2006 Jul 3.</reference_text>
        <pubmed_id>17164136</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>FitzGerald GA: COX-2 in play at the AHA and the FDA.  Trends Pharmacol Sci. 2007 Jul;28(7):303-7. Epub 2007 Jun 18.</reference_text>
        <pubmed_id>17573128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Yuan Y, Hunt RH: Global gastrointestinal safety profile of etoricoxib and lumiracoxib.  Curr Pharm Des. 2007;13(22):2237-47.</reference_text>
        <pubmed_id>17691997</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Niflumic Acid</name>
        <accession>HMDB15573</accession>
      </metabolite>
      <reference>
        <reference_text>Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, Dey S, Singh TP: Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86. Epub 2005 Nov       19.</reference_text>
        <pubmed_id>16301791</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Niflumic Acid</name>
        <accession>HMDB15573</accession>
      </metabolite>
      <reference>
        <reference_text>Diao HL, Zhu H, Ma H, Tan HN, Cong J, Su RW, Yang ZM: Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42.</reference_text>
        <pubmed_id>17485303</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Niflumic Acid</name>
        <accession>HMDB15573</accession>
      </metabolite>
      <reference>
        <reference_text>Alpert E, Gruzman A, Tennenbaum T, Sasson S: Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase Cdelta-dependent manner. Biochem Pharmacol. 2007 Feb 1;73(3):368-77. Epub 2006 Oct 13.</reference_text>
        <pubmed_id>17098211</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Substance P</name>
        <accession>HMDB01897</accession>
      </metabolite>
      <reference>
        <reference_text>Koon HW, Zhao D, Zhan Y, Rhee SH, Moyer MP, Pothoulakis C: Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J Immunol. 2006 Apr 15;176(8):5050-9.</reference_text>
        <pubmed_id>16585602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Substance P</name>
        <accession>HMDB01897</accession>
      </metabolite>
      <reference>
        <reference_text>Sio SW, Ang SF, Lu J, Moochhala S, Bhatia M: Substance P upregulates cyclooxygenase-2 and prostaglandin E metabolite by activating ERK1/2 and NF-kappaB in a mouse model of burn-induced remote acute lung injury. J Immunol. 2010 Nov 15;185(10):6265-76. Epub 2010 Oct 6.</reference_text>
        <pubmed_id>20926798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Substance P</name>
        <accession>HMDB01897</accession>
      </metabolite>
      <reference>
        <reference_text>Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, Fantozzi R: Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Br J Pharmacol. 2006 Mar;147(6):681-9.</reference_text>
        <pubmed_id>16432508</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lornoxicam</name>
        <accession>HMDB15666</accession>
      </metabolite>
      <reference>
        <reference_text>Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. Epub 2010 Jan 27.</reference_text>
        <pubmed_id>20399943</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lornoxicam</name>
        <accession>HMDB15666</accession>
      </metabolite>
      <reference>
        <reference_text>Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.</reference_text>
        <pubmed_id>10450786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lornoxicam</name>
        <accession>HMDB15666</accession>
      </metabolite>
      <reference>
        <reference_text>Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36.</reference_text>
        <pubmed_id>17516707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lornoxicam</name>
        <accession>HMDB15666</accession>
      </metabolite>
      <reference>
        <reference_text>Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5.</reference_text>
        <pubmed_id>11846620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nepafenac</name>
        <accession>HMDB15678</accession>
      </metabolite>
      <reference>
        <reference_text>Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.</reference_text>
        <pubmed_id>10850857</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nonoxynol-9</name>
        <accession>HMDB15680</accession>
      </metabolite>
      <reference>
        <reference_text>Zalenskaya IA, Cerocchi OG, Joseph T, Donaghay MA, Schriver SD, Doncel GF: Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection. Am J Reprod Immunol. 2011 Jun;65(6):569-77. doi:       10.1111/j.1600-0897.2010.00964.x. Epub 2011 Jan 18.</reference_text>
        <pubmed_id>21241401</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
